Genetics Institute, Transkaryotic deal

TKT licensed the rights to GENIZ's Factor VIII gene for the development of gene therapy products to treat hemophilia A. TKT will have exclusive worldwide rights to market products, excluding Europe. GENIZ will have marketing rights in Europe, while TKT retains exclusive worldwide manufacturing rights. The companies will jointly develop and fund a clinical program for the products. ...